Neoplasia/BPH

	Salvage prostatectomy for locally recurrent prostate cancer after radiation: a narrative review of indications, outcomes, and surgical advancements. World J Urol Lee MS, Karnes RJ. PMID: 42262568 [PubMed - in process]
	KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma. Expert Rev Mol Diagn Rosellini M, Danielli L, Bibbò A, Musio M, Ricci C, Piazza P, Santoni M, Mollica V, Massari F. PMID: 42261901 [PubMed - as supplied by publisher]
	A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer. Future Oncol Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K. PMID: 42261883 [PubMed - as supplied by publisher]
	Development and interpretability of a machine learning-derived model for the identification of latent prostate cancer in patients initially diagnosed with benign prostatic hyperplasia: a retrospective cohort study. BMC Med Inform Decis Mak Liang S, Lao Y, Ma P, Shang C, Li R, Li Z, Le Y, Cao W, Chen C, Liu K, Li L. PMID: 42260550 [PubMed - as supplied by publisher]
	Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances. BMC Urol Alasker A, Alghafees M, Nammor T, Alanazi N, Alferayan T, Almanie A, Alrashed M, Almarzouq Y, Alammari A. PMID: 42260513 [PubMed - as supplied by publisher]
	Integrated multi-omics profiling uncovers the epigenetic, transcriptional, and metabolic landscape of prostate cancer progression. BMC Cancer Pedersen CA, Wess M, Andersen MK, Midtbust E, Sharma A, Fleischer T, Rye MB, Tessem MB. PMID: 42260416 [PubMed - as supplied by publisher]
	Integrating DNA methylation and clinical features to predict prostate cancer prognosis. BMC Cancer Qian Y, Zhu W, Fang Z, Luo Z, Xie W, Cao Y, Chen W, Fu H, Peng J, Zhang L, Lei S, Jin J, Li J, Zhao X, Gong Z, Zhang D, He Y. PMID: 42260380 [PubMed - as supplied by publisher]
	177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil. EJNMMI Rep Bruzzi HF, Lopes GCK, Bekierman HBV, de Almeida SA, Pedrosa JA, Mosci C, Abboud HS, Magalhães C, Palazzio I, Fernandes L, da Silva VF, da Silva Andrade JT, Herchenhorn D. PMID: 42260246 [PubMed]
	More harm than good? The UK National Screening Committee's latest review of prostate cancer screening. BJU Int Boshari T, Anderson A, Richards M. PMID: 42259762 [PubMed - as supplied by publisher]
	Impact of a commercial artificial intelligence decision-support system on biparametric MRI interpretation for detecting clinically significant prostate cancer: a retrospective single-center prostatectomy-validated multi-reader study across experience levels. Eur J Radiol Higaki A, Tamada T, Takeuchi M, Ueda Y, Kojima Y, Maruhisa T, Watanabe H, Moriya K, Kagioka H, Yamamoto A. PMID: 42258918 [PubMed - as supplied by publisher]
	A study on the effects of intrafractional changes in bladder volume on positional accuracy and target dosimetry in online adaptive radiotherapy for cervical cancer. Appl Radiat Isot Chi F, Jiang X, Zhou W, Chen Z, Shang L, Zheng W, Gu C, Mai X, Lin L, Chen F, Qi Y. PMID: 42258914 [PubMed - as supplied by publisher]
	Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients. Transl Behav Med Garcia RS, Daniel CR, Hwang C, Levy E, Smith M, Cho D, Frigo DE, Hahn AW, Ma H, Robert M, Pettaway C, Chapin BF, LaRue D, Canfield S, Wargo J, Wei P, McNeill L, Gregg JR. PMID: 42258524 [PubMed - in process]
	Real-world comparison of androgen receptor pathway Ä±nhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer. Curr Med Res Opin Birsin Z, Aliyev V, Cebeci S, Guliyev M, Jeral Evinç S, Çerme E, Günalt, Abbasov H, Çiçek E, Fidan MC, Demirci NS, Alan Ö. PMID: 42258330 [PubMed - as supplied by publisher]
	Correction to: Real-world efficacy of switching androgen receptor signaling inhibitor therapy following apalutamide discontinuation because of adverse events in advanced prostate cancer: a multicenter study. Jpn J Clin Oncol PMID: 42258144 [PubMed - as supplied by publisher]
	Clinical and pathological factors associated with recurrence after radical cystectomy for bladder cancer: A single-center retrospective study. Pak J Med Sci Nusrat NB, Imtiaz S, Aslam A, Rehman AU, Muhammad S, Zafar N, Ashfaq AM, Arshad H. PMID: 42257077 [PubMed]
	Association of long-term 5Î±-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study. Front Pharmacol Lee S, Lee J, Min K, Tae JH, Lee CU, Choi J, Kim JH, Lee YS, Nguyen TT, Choi SY. PMID: 42256393 [PubMed]
	Assessing the hepatic and renal parameters of breast cancer patient blood samples before and after chemotherapy. Toxicol Rep Heilat GB, Alwidyan T, Alrosan AZ, Rataan AO, Alrosan K, Ahmad RB, Al-Kammash KR. PMID: 42255660 [PubMed]
	Progression-free Survival Following Primary Staging with [(18)F]PSMA-1007-PET/ceCT Versus Na[(18)F]F-PET/ceCT in Prostate Cancer: Results from the PRISMA-PET Randomized Controlled Trial. Eur Urol Open Sci Buch-Olsen KM, Hansen S, Vilstrup MH, Poulsen MH, Holdgaard PC, Zieger KEA, Asmussen JT, Holm J, Pedersen KT, Hess S, Madsen SS, Eiber M, Gerke O, Hildebrandt MG. PMID: 42255253 [PubMed]
	The role of lysophosphatidic acid metabolism in castration-resistant prostate cancer progression. Front Oncol Feng J, Liu J, He Y. PMID: 42255241 [PubMed]
	Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis. Front Oncol Yuan W, Wang Y, Liu Q, Tian F, Guo M. PMID: 42255215 [PubMed]

Articles 1 - 20 / 188416

Page 1 of 9421



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy